Neurogen Corporation Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson’s Disease
October 13th, 2008
BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN - News) today announced positive top-line results from two Phase 2 clinical trials in restless legs syndrome (RLS) and Parkinsons disease with the Companys dopamine partial agonist, aplindore. These studies were the first in which aplindore has been evaluated in RLS and Parkinsons disease.
This entry was posted on Monday, October 13th, 2008 at 5:00 pm and is filed under Industry News.
Print This Post.
In each study, aplindore demonstrated...
- Share/Bookmark:
Print This Post.